drugset / Trial / NCT05028751
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML).
Timeline
- Start
- 2022-08-05
- Primary completion
- 2024-04-09
- Completion
- 2024-04-09
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gilteritinib | Small molecule | 120 mg | Oral |
| Subject | Lanraplenib | Small molecule | 20 mg | Oral |
| Subject | Lanraplenib | Small molecule | 40 mg | Oral |
| Subject | Lanraplenib | Small molecule | 60 mg | Oral |
| Subject | Lanraplenib | Small molecule | 90 mg | Oral |